Nurix Therapeutics Inc.

NASDAQ: NRIX · Real-Time Price · USD
10.57
0.01 (0.09%)
At close: Aug 15, 2025, 3:59 PM
10.45
-1.14%
After-hours: Aug 15, 2025, 04:10 PM EDT

Nurix Therapeutics Income Statement

Financials in USD. Fiscal year is December - November.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Nov 30, 2024 Nov 30, 2023 Nov 30, 2022 Nov 30, 2021
Revenue
54.55M 76.99M 38.63M 29.75M
Cost of Revenue
16.43M 189.15M 10.81M 6.08M
Gross Profit
38.12M -112.16M 27.82M 23.67M
Operating Income
-213.03M -155.06M -183.87M -117.89M
Interest Income
19.73M 11.12M 3.51M 823K
Pretax Income
-193.3M -143.95M -180.36M -117.06M
Net Income
-193.57M -143.95M -166.04M -117.19M
Selling & General & Admin
45.94M 42.9M 38M 31.2M
Research & Development
221.63M 189.15M 184.5M 116.43M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
267.58M 232.05M 222.49M 147.64M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
267.58M 232.05M 222.49M 147.64M
Income Tax Expense
270K n/a -14.31M 131K
Shares Outstanding (Basic)
67.12M 54.34M 48.61M 42.9M
Shares Outstanding (Diluted)
67.12M 54.34M 48.61M 42.9M
EPS (Basic)
-2.88 -2.65 -3.42 -2.73
EPS (Diluted)
-2.88 -2.65 -3.42 -2.73
EBITDA
-196.6M -141.41M -173.06M -111.8M
EBIT
-213.03M -155.06M -183.87M -117.89M
Depreciation & Amortization
16.43M 13.65M 10.81M 6.08M